A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents
Latest Information Update: 22 Apr 2022
At a glance
- Drugs MVC COV1901 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medigen Vaccine Biologics
- 19 Apr 2022 Status changed from active, no longer recruiting to completed.
- 27 Jan 2022 Planned End Date changed from 1 May 2022 to 1 Apr 2022.
- 02 Nov 2021 Status changed from recruiting to active, no longer recruiting.